Skip to main content
Top
Published in: Abdominal Radiology 1/2024

10-10-2023 | Magnetic Resonance Imaging | Hepatobiliary

Preoperative MRI features predicting very early recurrence of intrahepatic mass-forming cholangiocarcinoma after R0 resection: a comparison with the AJCC 8th edition staging system

Authors: Shuang Chen, Lijuan Wan, Rui Zhao, Wenjing Peng, Shuangmei Zou, Hongmei Zhang

Published in: Abdominal Radiology | Issue 1/2024

Login to get access

Abstract

Purpose

This study aimed to establish a nomogram based on preoperative magnetic resonance imaging (MRI) features to predict the very early recurrence (VER, less than 6 months) of intrahepatic mass-forming cholangiocarcinoma (IMCC) after R0 resection.

Methods

This study enrolled a group of 193 IMCC patients from our institution between March 2010 and January 2022. Patients were allocated into the development cohort (= 137) and the validation cohort (= 56), randomly, and the preoperative clinical and MRI features were collected. Univariate and multivariate stepwise logistic regression assessments were adopted to assess predictors of VER. Nomogram was constructed and certificated in the validation cohort. The performance of the prediction nomogram was evaluated by its discrimination, calibration, and clinical utility. The performance of the nomogram was compared with the T stage of the American Joint Committee on Cancer (AJCC) 8th edition staging system.

Results

Fifty-three patients (27.5%) experienced VER of the tumor and 140 patients (72.5%) with non-VER, during the follow-up period. After multivariate stepwise logistic regression, number of lesions, diffuse hypoenhancement on arterial phase, necorsis and suspicious lymph nodes were independently associated with VER. The nomogram demonstrated significantly higher area under the curve (AUC) of 0.813 than T stage (AUC = 0.666, P = 0.006) in the development cohort, whereas in the validation cohort, the nomogram showed better discrimination performance, with an AUC of 0.808 than T stage (0.705) with no significantly difference (P = 0.230). Decision curve analysis reflected the clinical net benefit of the nomogram.

Conclusion

The nomogram based on preoperative MRI features is a reliable tool to predict VER for patients with IMCC after R0 resection. This nomogram will be helpful to improve survival prediction and individualized treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag H B, La Vecchia C and Negri E, Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol 2019; 71: 104-114.CrossRefPubMed Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag H B, La Vecchia C and Negri E, Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol 2019; 71: 104-114.CrossRefPubMed
2.
go back to reference Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B and Carpino G, Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int 2019; 39 Suppl 1: 7-18.CrossRefPubMed Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B and Carpino G, Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int 2019; 39 Suppl 1: 7-18.CrossRefPubMed
3.
go back to reference Littau M J, Kim P, Kulshrestha S, Bunn C, Tonelli C, Abdelsattar Z M, Luchette F A and Baker M S, Resectable intrahepatic and hilar cholangiocarcinoma: Is margin status associated with survival? Surgery 2022; 171: 703-710.CrossRefPubMed Littau M J, Kim P, Kulshrestha S, Bunn C, Tonelli C, Abdelsattar Z M, Luchette F A and Baker M S, Resectable intrahepatic and hilar cholangiocarcinoma: Is margin status associated with survival? Surgery 2022; 171: 703-710.CrossRefPubMed
4.
go back to reference Mazzaferro V, Gorgen A, Roayaie S, Dit Busset M D and Sapisochin G, Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol 2020; 72: 364-377.CrossRefPubMed Mazzaferro V, Gorgen A, Roayaie S, Dit Busset M D and Sapisochin G, Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol 2020; 72: 364-377.CrossRefPubMed
5.
go back to reference Zhang X F, Beal E W, Bagante F, Chakedis J, Weiss M, Popescu I, Marques H P, Aldrighetti L, Maithel S K, Pulitano C, Bauer T W, Shen F, Poultsides G A, Soubrane O, Martel G, Koerkamp B G, Itaru E and Pawlik T M, Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg 2018; 105: 848-856.CrossRefPubMed Zhang X F, Beal E W, Bagante F, Chakedis J, Weiss M, Popescu I, Marques H P, Aldrighetti L, Maithel S K, Pulitano C, Bauer T W, Shen F, Poultsides G A, Soubrane O, Martel G, Koerkamp B G, Itaru E and Pawlik T M, Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg 2018; 105: 848-856.CrossRefPubMed
6.
go back to reference Zhao L, Ma X, Liang M, Li D, Ma P, Wang S, Wu Z and Zhao X, Prediction for early recurrence of intrahepatic mass-forming cholangiocarcinoma: quantitative magnetic resonance imaging combined with prognostic immunohistochemical markers. Cancer Imaging 2019; 19: 49.CrossRefPubMedPubMedCentral Zhao L, Ma X, Liang M, Li D, Ma P, Wang S, Wu Z and Zhao X, Prediction for early recurrence of intrahepatic mass-forming cholangiocarcinoma: quantitative magnetic resonance imaging combined with prognostic immunohistochemical markers. Cancer Imaging 2019; 19: 49.CrossRefPubMedPubMedCentral
7.
go back to reference Tsilimigras D I, Sahara K, Wu L, Moris D, Bagante F, Guglielmi A et al., Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma: Considering Alternative Treatment Approaches. JAMA Surg 2020; 155: 823-831.CrossRefPubMed Tsilimigras D I, Sahara K, Wu L, Moris D, Bagante F, Guglielmi A et al., Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma: Considering Alternative Treatment Approaches. JAMA Surg 2020; 155: 823-831.CrossRefPubMed
8.
go back to reference Tsilimigras D I and Pawlik T M, Preoperative Model and Patient Selection for Neoadjuvant Therapy for Intrahepatic Cholangiocarcinoma-Reply. JAMA Surg 2021; 156: 395-396.CrossRefPubMed Tsilimigras D I and Pawlik T M, Preoperative Model and Patient Selection for Neoadjuvant Therapy for Intrahepatic Cholangiocarcinoma-Reply. JAMA Surg 2021; 156: 395-396.CrossRefPubMed
9.
go back to reference Yadav S, Xie H, Bin-Riaz I, Sharma P, Durani U, Goyal G, Borah B, Borad M J, Smoot R L, Roberts L R, Go R S, McWilliams R R and Mahipal A, Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. Eur J Surg Oncol 2019; 45: 1432-1438.CrossRefPubMed Yadav S, Xie H, Bin-Riaz I, Sharma P, Durani U, Goyal G, Borah B, Borad M J, Smoot R L, Roberts L R, Go R S, McWilliams R R and Mahipal A, Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. Eur J Surg Oncol 2019; 45: 1432-1438.CrossRefPubMed
10.
go back to reference Chun Y S, Pawlik T M and Vauthey J N, 8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers. Ann Surg Oncol 2018; 25: 845-847.CrossRefPubMed Chun Y S, Pawlik T M and Vauthey J N, 8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers. Ann Surg Oncol 2018; 25: 845-847.CrossRefPubMed
11.
go back to reference Sasaki K, Margonis G A, Andreatos N, Chen Q, Barbon C, Bagante F et al., Serum tumor markers enhance the predictive power of the AJCC and LCSGJ staging systems in resectable intrahepatic cholangiocarcinoma. HPB (Oxford) 2018; 20: 956-965.CrossRefPubMed Sasaki K, Margonis G A, Andreatos N, Chen Q, Barbon C, Bagante F et al., Serum tumor markers enhance the predictive power of the AJCC and LCSGJ staging systems in resectable intrahepatic cholangiocarcinoma. HPB (Oxford) 2018; 20: 956-965.CrossRefPubMed
12.
go back to reference Buettner S, Galjart B, van Vugt J L A, Bagante F, Alexandrescu S, Marques H P et al., Performance of prognostic scores and staging systems in predicting long-term survival outcomes after surgery for intrahepatic cholangiocarcinoma. J Surg Oncol 2017; 116: 1085-1095.CrossRefPubMed Buettner S, Galjart B, van Vugt J L A, Bagante F, Alexandrescu S, Marques H P et al., Performance of prognostic scores and staging systems in predicting long-term survival outcomes after surgery for intrahepatic cholangiocarcinoma. J Surg Oncol 2017; 116: 1085-1095.CrossRefPubMed
13.
go back to reference Granata V, Grassi R, Fusco R, Setola S V, Belli A, Ottaiano A, Nasti G, La Porta M, Danti G, Cappabianca S, Cutolo C, Petrillo A and Izzo F, Intrahepatic cholangiocarcinoma and its differential diagnosis at MRI: how radiologist should assess MR features. Radiol Med 2021; 126: 1584-1600.CrossRefPubMed Granata V, Grassi R, Fusco R, Setola S V, Belli A, Ottaiano A, Nasti G, La Porta M, Danti G, Cappabianca S, Cutolo C, Petrillo A and Izzo F, Intrahepatic cholangiocarcinoma and its differential diagnosis at MRI: how radiologist should assess MR features. Radiol Med 2021; 126: 1584-1600.CrossRefPubMed
14.
15.
go back to reference Min J H, Kim Y K, Choi S Y, Kang T W, Lee S J, Kim J M, Ahn S and Cho H, Intrahepatic Mass-forming Cholangiocarcinoma: Arterial Enhancement Patterns at MRI and Prognosis. Radiology 2019; 290: 691-699.CrossRefPubMed Min J H, Kim Y K, Choi S Y, Kang T W, Lee S J, Kim J M, Ahn S and Cho H, Intrahepatic Mass-forming Cholangiocarcinoma: Arterial Enhancement Patterns at MRI and Prognosis. Radiology 2019; 290: 691-699.CrossRefPubMed
16.
go back to reference Promsorn J, Eurboonyanun K, Chadbunchachai P, Apivatanasiri C, Wirasorn K, Chindaprasirt J, Sookprasert A and Harisinghani M, Diffusion-weighted imaging as an imaging biomarker for assessing survival of patients with intrahepatic mass-forming cholangiocarcinoma. Abdom Radiol (NY) 2022; 47: 2811-2821.CrossRefPubMed Promsorn J, Eurboonyanun K, Chadbunchachai P, Apivatanasiri C, Wirasorn K, Chindaprasirt J, Sookprasert A and Harisinghani M, Diffusion-weighted imaging as an imaging biomarker for assessing survival of patients with intrahepatic mass-forming cholangiocarcinoma. Abdom Radiol (NY) 2022; 47: 2811-2821.CrossRefPubMed
17.
go back to reference Liang W, Xu L, Yang P, Zhang L, Wan D, Huang Q, Niu T and Chen F, Novel Nomogram for Preoperative Prediction of Early Recurrence in Intrahepatic Cholangiocarcinoma. Front Oncol 2018; 8: 360.CrossRefPubMedPubMedCentral Liang W, Xu L, Yang P, Zhang L, Wan D, Huang Q, Niu T and Chen F, Novel Nomogram for Preoperative Prediction of Early Recurrence in Intrahepatic Cholangiocarcinoma. Front Oncol 2018; 8: 360.CrossRefPubMedPubMedCentral
18.
go back to reference Sheng R, Huang X, Jin K, Gao S, Zeng M, Wu D and Shi G, Contrast-enhanced MRI could predict response of systemic therapy in advanced intrahepatic cholangiocarcinoma. Eur Radiol 2022; 32: 5156-5165.CrossRefPubMed Sheng R, Huang X, Jin K, Gao S, Zeng M, Wu D and Shi G, Contrast-enhanced MRI could predict response of systemic therapy in advanced intrahepatic cholangiocarcinoma. Eur Radiol 2022; 32: 5156-5165.CrossRefPubMed
19.
go back to reference Lee A J and Chun Y S, Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates. Chin Clin Oncol 2018; 7: 52. Lee A J and Chun Y S, Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates. Chin Clin Oncol 2018; 7: 52.
20.
22.
go back to reference Wu Y, Liu H, Zeng J, Chen Y, Fang G, Zhang J, Zhou W, Zeng Y and Liu J, Development and validation of nomogram to predict very early recurrence of combined hepatocellular-cholangiocarcinoma after hepatic resection: a multi-institutional study. World J Surg Oncol 2022; 20: 60.CrossRefPubMedPubMedCentral Wu Y, Liu H, Zeng J, Chen Y, Fang G, Zhang J, Zhou W, Zeng Y and Liu J, Development and validation of nomogram to predict very early recurrence of combined hepatocellular-cholangiocarcinoma after hepatic resection: a multi-institutional study. World J Surg Oncol 2022; 20: 60.CrossRefPubMedPubMedCentral
23.
go back to reference Hirokawa F, Hayashi M, Asakuma M, Shimizu T, Inoue Y and Uchiyama K, Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma. Surg Oncol 2016; 25: 24-9.CrossRefPubMed Hirokawa F, Hayashi M, Asakuma M, Shimizu T, Inoue Y and Uchiyama K, Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma. Surg Oncol 2016; 25: 24-9.CrossRefPubMed
24.
go back to reference Mason M C, Massarweh N N, Tzeng C D, Chiang Y J, Chun Y S, Aloia T A, Javle M, Vauthey J N and Tran Cao H S, Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience. Ann Surg Oncol 2021; 28: 6725-6735.CrossRefPubMed Mason M C, Massarweh N N, Tzeng C D, Chiang Y J, Chun Y S, Aloia T A, Javle M, Vauthey J N and Tran Cao H S, Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience. Ann Surg Oncol 2021; 28: 6725-6735.CrossRefPubMed
25.
go back to reference Utuama O, Permuth J B, Dagne G, Sanchez-Anguiano A, Alman A, Kumar A, Denbo J, Kim R, Fleming J B and Anaya D A, Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease. Ann Surg Oncol 2021; 28: 1939-1949.CrossRefPubMed Utuama O, Permuth J B, Dagne G, Sanchez-Anguiano A, Alman A, Kumar A, Denbo J, Kim R, Fleming J B and Anaya D A, Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease. Ann Surg Oncol 2021; 28: 1939-1949.CrossRefPubMed
26.
go back to reference Jin K P, Sheng R F, Yang C and Zeng M S, Combined arterial and delayed enhancement patterns of MRI assist in prognostic prediction for intrahepatic mass-forming cholangiocarcinoma (IMCC). Abdom Radiol (NY) 2022; 47: 640-650.CrossRefPubMed Jin K P, Sheng R F, Yang C and Zeng M S, Combined arterial and delayed enhancement patterns of MRI assist in prognostic prediction for intrahepatic mass-forming cholangiocarcinoma (IMCC). Abdom Radiol (NY) 2022; 47: 640-650.CrossRefPubMed
27.
go back to reference King M J, Hectors S, Lee K M, Omidele O, Babb J S, Schwartz M, Tabrizian P, Taouli B and Lewis S, Outcomes assessment in intrahepatic cholangiocarcinoma using qualitative and quantitative imaging features. Cancer Imaging 2020; 20: 43.CrossRefPubMedPubMedCentral King M J, Hectors S, Lee K M, Omidele O, Babb J S, Schwartz M, Tabrizian P, Taouli B and Lewis S, Outcomes assessment in intrahepatic cholangiocarcinoma using qualitative and quantitative imaging features. Cancer Imaging 2020; 20: 43.CrossRefPubMedPubMedCentral
28.
go back to reference Baheti A D, Tirumani S H, Rosenthal M H, Shinagare A B and Ramaiya N H, Diagnosis and management of intrahepatic cholangiocarcinoma: a comprehensive update for the radiologist. Clin Radiol 2014; 69: e463-70.CrossRefPubMed Baheti A D, Tirumani S H, Rosenthal M H, Shinagare A B and Ramaiya N H, Diagnosis and management of intrahepatic cholangiocarcinoma: a comprehensive update for the radiologist. Clin Radiol 2014; 69: e463-70.CrossRefPubMed
29.
go back to reference Sulpice L, Rayar M, Desille M, Turlin B, Fautrel A, Boucher E, Llamas-Gutierrez F, Meunier B, Boudjema K, Clément B and Coulouarn C, Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology 2013; 58: 1992-2000.CrossRefPubMed Sulpice L, Rayar M, Desille M, Turlin B, Fautrel A, Boucher E, Llamas-Gutierrez F, Meunier B, Boudjema K, Clément B and Coulouarn C, Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology 2013; 58: 1992-2000.CrossRefPubMed
30.
go back to reference Atanasov G, Dietel C, Feldbrügge L, Benzing C, Krenzien F, Brandl A, Mann E, Englisch J P, Schierle K, Robson S C, Splith K, Morgul M H, Reutzel-Selke A, Jonas S, Pascher A, Bahra M, Pratschke J and Schmelzle M, Tumor necrosis and infiltrating macrophages predict survival after curative resection for cholangiocarcinoma. Oncoimmunology 2017; 6: e1331806.CrossRefPubMedPubMedCentral Atanasov G, Dietel C, Feldbrügge L, Benzing C, Krenzien F, Brandl A, Mann E, Englisch J P, Schierle K, Robson S C, Splith K, Morgul M H, Reutzel-Selke A, Jonas S, Pascher A, Bahra M, Pratschke J and Schmelzle M, Tumor necrosis and infiltrating macrophages predict survival after curative resection for cholangiocarcinoma. Oncoimmunology 2017; 6: e1331806.CrossRefPubMedPubMedCentral
31.
go back to reference Atanasov G, Schierle K, Hau H M, Dietel C, Krenzien F, Brandl A, Wiltberger G, Englisch J P, Robson S C, Reutzel-Selke A, Pascher A, Jonas S, Pratschke J, Benzing C and Schmelzle M, Prognostic Significance of Tumor Necrosis in Hilar Cholangiocarcinoma. Ann Surg Oncol 2017; 24: 518-525.CrossRefPubMed Atanasov G, Schierle K, Hau H M, Dietel C, Krenzien F, Brandl A, Wiltberger G, Englisch J P, Robson S C, Reutzel-Selke A, Pascher A, Jonas S, Pratschke J, Benzing C and Schmelzle M, Prognostic Significance of Tumor Necrosis in Hilar Cholangiocarcinoma. Ann Surg Oncol 2017; 24: 518-525.CrossRefPubMed
32.
go back to reference Tsilimigras D I, Ejaz A, Cloyd J, Guglielmi A, Aldrighetti L, Weiss M, Bauer T W, Alexandrescu S, Poultsides G A, Maithel S K, Marques H P, Martel G, Pulitano C, Shen F, Soubrane O, Koerkamp B G, Endo I and Pawlik T M, Tumor Necrosis Impacts Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma. Ann Surg Oncol 2022. https://doi.org/10.1245/s10434-022-11462-yCrossRefPubMed Tsilimigras D I, Ejaz A, Cloyd J, Guglielmi A, Aldrighetti L, Weiss M, Bauer T W, Alexandrescu S, Poultsides G A, Maithel S K, Marques H P, Martel G, Pulitano C, Shen F, Soubrane O, Koerkamp B G, Endo I and Pawlik T M, Tumor Necrosis Impacts Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma. Ann Surg Oncol 2022. https://​doi.​org/​10.​1245/​s10434-022-11462-yCrossRefPubMed
33.
go back to reference Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, Wan X, Liu G, Wu D, Shi L, Lau W, Wu M and Shen F, Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol 2013; 31: 1188-95.CrossRefPubMed Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, Wan X, Liu G, Wu D, Shi L, Lau W, Wu M and Shen F, Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol 2013; 31: 1188-95.CrossRefPubMed
34.
go back to reference Hyder O, Marques H, Pulitano C, Marsh J W, Alexandrescu S, Bauer T W, Gamblin T C, Sotiropoulos G C, Paul A, Barroso E, Clary B M, Aldrighetti L, Ferrone C R, Zhu A X, Popescu I, Gigot J F, Mentha G, Feng S and Pawlik T M, A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg 2014; 149: 432-8.CrossRefPubMed Hyder O, Marques H, Pulitano C, Marsh J W, Alexandrescu S, Bauer T W, Gamblin T C, Sotiropoulos G C, Paul A, Barroso E, Clary B M, Aldrighetti L, Ferrone C R, Zhu A X, Popescu I, Gigot J F, Mentha G, Feng S and Pawlik T M, A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg 2014; 149: 432-8.CrossRefPubMed
35.
go back to reference Amin M B, Greene F L, Edge S B, Compton C C, Gershenwald J E, Brookland R K, Meyer L, Gress D M, Byrd D R and Winchester D P, The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin 2017; 67: 93-99.CrossRef Amin M B, Greene F L, Edge S B, Compton C C, Gershenwald J E, Brookland R K, Meyer L, Gress D M, Byrd D R and Winchester D P, The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin 2017; 67: 93-99.CrossRef
36.
go back to reference Zhou S N, Lu S S, Ju D W, Yu L X, Liang X X, Xiang X, Liangpunsakul S, Roberts L R, Lu Y Y and Zhang N, A New Prognostic Model Covering All Stages of Intrahepatic Cholangiocarcinoma. J Clin Transl Hepatol 2022; 10: 254-262.CrossRefPubMed Zhou S N, Lu S S, Ju D W, Yu L X, Liang X X, Xiang X, Liangpunsakul S, Roberts L R, Lu Y Y and Zhang N, A New Prognostic Model Covering All Stages of Intrahepatic Cholangiocarcinoma. J Clin Transl Hepatol 2022; 10: 254-262.CrossRefPubMed
37.
go back to reference Rhee H, Choi S H, Park J H, Cho E S, Yeom S K, Park S, Han K, Lee S S and Park M S, Preoperative magnetic resonance imaging-based prognostic model for mass-forming intrahepatic cholangiocarcinoma. Liver Int 2022; 42: 930-941.CrossRefPubMed Rhee H, Choi S H, Park J H, Cho E S, Yeom S K, Park S, Han K, Lee S S and Park M S, Preoperative magnetic resonance imaging-based prognostic model for mass-forming intrahepatic cholangiocarcinoma. Liver Int 2022; 42: 930-941.CrossRefPubMed
Metadata
Title
Preoperative MRI features predicting very early recurrence of intrahepatic mass-forming cholangiocarcinoma after R0 resection: a comparison with the AJCC 8th edition staging system
Authors
Shuang Chen
Lijuan Wan
Rui Zhao
Wenjing Peng
Shuangmei Zou
Hongmei Zhang
Publication date
10-10-2023
Publisher
Springer US
Published in
Abdominal Radiology / Issue 1/2024
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-023-04038-1

Other articles of this Issue 1/2024

Abdominal Radiology 1/2024 Go to the issue

Classics in Abdominal Radiology

Honeycomb sign in melioidosis

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine